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Neuropeptide B/W receptor-1 (NPBWR1) and NPBWR2 had been known as orphan recep-
tors GPR7 and 8, respectively. Endogenous peptide ligands of these receptors, neuropep-
tide B (NPB) and neuropeptide W (NPW), were identified in 2002 and 2003 (Fujii et al.,
2002; Brezillon et al., 2003; Tanaka et al., 2003). These peptides have been implicated in
regulation of feeding behavior, energy homeostasis, neuroendocrine function, and modu-
lating inflammatory pain. In addition, strong and discrete expression of their receptors in
the extended amygdala and bed nucleus of the stria terminalis suggests a potential role in
regulating stress responses, emotion, anxiety, and fear. Recent studies of NPB/NPW using
both pharmacological and phenotypic analyses of genetically engineered mice as well as
a human study support this hypothesis.
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INTRODUCTION
Receptors for neuropeptide B (NPB)/neuropeptide W (NPW)
were originally identified as orphan receptors GPR7 and GPR8,
which share 70% nucleotide identity and 64% amino acid identity
with each other. They have relatively high similarities with opioid
and somatostatin receptors. GPR8 was not found in the rodent
genomes, while GPR7 was highly conserved in both human and
rodents (O’Dowd et al., 1995). This suggests the GPR8 gene was
relatively recently generated through gene duplication.
In 2002–2003, two endogenous peptide ligands for these recep-
tors were identified and named NPB/NPW (Fujii et al., 2002;
Shimomura et al., 2002; Brezillon et al., 2003; Tanaka et al., 2003).
Following the deorphaning of these receptors, GPR7 and GPR8
were reclassified by IUPHAR as NPB/W receptor-1 (NPBWR1)
and NPB/W receptor-2 (NPBWR2), respectively (Davenport and
Singh, 2005).
In rodents, Npbwr1 mRNA is localized in some discrete brain
regions, including the hypothalamus (dorsomedial hypothalamus
and suprachiasmatic nucleus), hippocampus, ventral tegmental
area (VTA), and extended amygdala (CeA and bed nucleus of
the stria terminalis; BNST) (Lee et al., 1999; Tanaka et al., 2003),
suggesting this receptor is involved in regulatory mechanisms of
homeostasis, reward system, and emotion.
This review discusses recent findings concerning the pharma-
cology, histology, and phenotypic analysis of genetically engi-
neered mice of the NPB/NPW system.
IDENTIFICATION OF NPB AND NPW
In 2002–2003, three groups independently identified endogenous
peptide ligands for GPR7 and GPR8 by so-called “reverse phar-
macology” in combination with bioinformatics approaches. To
identify the cognate endogenous ligands for GPR7 (NPBWR1)
and GPR8 (NPBWR2), Shimomura et al. (2002) expressed these
receptors in Chinese Hamster Ovary (CHO) cells and measured
the decrease in forskolin-induced cAMP production in these
cells as the read-out for receptor activation. While screening the
bovine hypothalamic extract fractions, they detected activities that
specifically inhibit cAMP production in those cells, and purified
the activities. During their purification process, they identified
two forms of NPW with different peptide lengths of 23 and
30 amino acid residues, and named them NPW23 and NPW30,
respectively.
In a similar manner, three groups (Fujii et al., 2002; Brezillon
et al., 2003; Tanaka et al., 2003) independently purified and identi-
fied an additional endogenous ligand for NPBW1 and NPBW2.
Fujii et al. first screened the Celera database to identify novel
secretory peptides and then expressed the cDNAs of the putative
secretory peptides to find novel peptide ligands. Subsequent phar-
macological studies and purification of the peptide from bovine
hypothalamic extracts led to identification of the second ligand
for GPR7 and GPR8, which was named NPB due to the unique
modification, namely, bromination of the first tryptophan residue.
Brezillon et al. (2003) also identified human NPB mRNA using a
bioinformatics approach by searching the EST database using the
NPW sequence as a query.
Tanaka et al. used a unique melanin-pigment aggregation assay
inXenopus melanophore cells expressing GPR7 as the assay system
to purify NPB from bovine hypothalamus. Through EST database
searches they also identified NPW as a putative paralogous peptide
(Tanaka et al., 2003).
STRUCTURES OF NPW AND NPB
Neuropeptide W and NPB do not display any significant sequence
similarity to members of other known peptide families, while
sharing a high degree of sequence similarity with each other, con-
stituting a distinct family of peptides (Figure 1A) (Fujii et al., 2002;
Shimomura et al., 2002; Brezillon et al., 2003; Tanaka et al., 2003).
As mentioned earlier, sequence analysis of purified peptides
showed that NPW has two isoforms with lengths of 23 and
30 amino acid residues, i.e., neuropeptide W23 (NPW23) and
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FIGURE 1 |The NPB/NPW system. (A) Amino acid sequences of NPB and
NPW. Dark shadow shows amino acid identity between NPB and NPW. Light
shadow shows conserved amino acids within NPB or NPW. (B) NPB/W and
their receptors. EC50 values were determined by assay of inhibition of cAMP
production in CHO cells expressing each receptor (Brezillon et al., 2003).
Modified from Hondo et al. (2008).
neuropeptide W30 (NPW30), respectively. NPW23 is produced
as a result of proteolytic processing at a pair of arginine residues in
the 24th and 25th positions in NPW30 (Fujii et al., 2002; Brezillon
et al., 2003; Tanaka et al., 2003). In vitro experiments using cells
expressing these receptors showed that synthetic NPW23 activates
and binds to both NPBWR1 and NPBWR2 at similar effective
doses, while NPW30 shows slightly lower affinity to both recep-
tors as compared with NPW23 (Figure 1B) (Brezillon et al., 2003;
Tanaka et al., 2003).
As mentioned earlier, NPB has a unique modification at the
N-terminus tryptophan residue, C-6-bromination (Fujii et al.,
2002; Tanaka et al., 2003). While this represents the first evi-
dence of bromination of the protein in mammals, the biological
significance of this modification is unclear, as it has been demon-
strated that des-bromo-NPB is equipotent to brominated NPB in
in vitro cAMP inhibition assays (Tanaka et al., 2003). By anal-
ogy with NPW, Brezillon et al. (2003) predicted that two isoforms
of NPB, NPB23 and NPB29, could be produced from the pro-
cessing of a 125-amino acid human precursor through the alter-
native usage of a dibasic amino acid pair. However, the dibasic
motif, Arg24–Arg25, which is seen in human NPB, does not exist
in NPB of other mammalian species including bovine, rat, and
mouse. Therefore, it is unlikely that the NPB23 isoform exists
as a mature peptide in non-human species. Consistently, both
Fujii et al. and Tanaka et al. were only able to isolate NPB29
from bovine hypothalamus extracts during their purification
procedures.
In X. laevis melanophore pigment aggregation assay, NPB29
binds and activates human NPBWR1 or NPBWR2 with median
effective concentrations (EC50) of 0.23 and 15.8 nM, respectively
(Tanaka et al., 2003), suggesting that NPB is a relatively selective
agonist for NPBWR1 (Figure 1B).
The preferred conformations of des-bromo-NPB and -NPW
have been determined by a combination of 1H NMR, CD, and
molecular modeling (Lucyk and Miskolzie, 2005).
STRUCTURE-ACTIVITY RELATIONSHIPS OF NPW AND NPB
The rank order of potency of NPB and NPW isoforms
has been determined in cell lines expressing NPBWR1 and
NPBWR2. Both NPW and NPB bind and activate NPBWR1 and
NPBWR2 receptors with varying degrees of affinity. NPBWR1 has
slightly higher affinity for NPB as compared with both forms
of NPW, whereas NPBWR2 shows a potency rank order of
NPW23>NPW30>NPB (Figure 1B) (Fujii et al., 2002; Shimo-
mura et al., 2002; Brezillon et al., 2003; Tanaka et al., 2003). NPB23
and NPB29 have similar affinity for both receptors. NPW23 and
NPW30 bind to both receptors almost equally, while NPB acts as
a relatively selective agonist for NPBWR1.
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Tanaka et al. (2003) showed that deletion of Trp-1 from NPB
or NPW markedly decreased their activity, suggesting that the N-
terminus is involved in receptor binding. This is consistent with
the fact that NPB and NPW have similarity in their sequences in
the N-terminal region.
STRUCTURES AND FUNCTIONS OF NPBWR1 AND NPBWR2
The human NPBWR1 and NPBWR2 genes are localized on
chromosome 10q11.2–121.1 and 20q13.3, respectively. Human
NPBWR1 and NPBWR2 have 328 and 333 amino acid residues,
respectively, and share 64% sequence homology with each other
(Figure 2). Among other family members of GPCRs, NPBW1
and NPBW2 are most closely related to opioid and somatostatin
receptors (Figure 2) (O’Dowd et al., 1995). Amino acid analysis of
NPBW1 orthologs in other mammalian species has revealed a high
degree of conservation throughout evolution (Lee et al., 1999). In
contrast, while the gene encoding NPBWR2 has been discovered in
several mammalian species such as monkey, lemur, bat, shrew, and
rabbit, it has not been found in rodent genomes (Lee et al., 1999),
suggesting that these two receptors were produced by relatively
phylogenetically recent gene duplication (Lee et al., 1999).
As suggested by the assay systems used during their purifi-
cation process and structural similarities to somatostatin/opioid
receptors, both NPBWR1 and NPBWR2 couple to the Gi-class
of G-proteins (Tanaka et al., 2003). This suggests that these neu-
ropeptides have inhibitory properties on neurons via activation of
GIRK (Kir3) channels. NPB and NPW were also shown to stim-
ulate Erk p42/p44 activity in human adrenocortical carcinoma-
derived NCI-H295 cells (Andreis et al., 2005). This activation is
probably mediated by beta/gamma subunits released from Gi-
proteins (Tim van et al., 1995). Recently, a synthetic low mole-
cular weight antagonist for NPBWR1 has been reported (Anthony
Romero et al., 2012).
DISTRIBUTION OF NPB/NPW AND NPBWR1/NPBWR2 IN
BRAIN AND OTHER TISSUE
NEUROPEPTIDE B
Npb mRNA was found in several specific regions in the mouse
brain such as the paraventricular hypothalamic nucleus (PVN),
CA1–CA3 fields of the hippocampus, and several nuclei in the
midbrain and brainstem, including the Edinger–Westphal (EW)
nucleus, the sensory and motor nuclei of the trigeminal nerve,
locus coeruleus (LC), inferior olive, and lateral parabrachial
nucleus (Figure 3) (Tanaka et al., 2003; Jackson et al., 2006).
Schulz et al. reported that NPB-immunoreactive cell bodies
were observed in many regions within the hypothalamus. High
levels of Npbwr1 and Npb mRNA expression were also observed
in the hypothalamus, including the ventromedial hypothalamic
FIGURE 2 | Primary structures of NPBWR1/NPBWR2 compared to somatostatin and opioid receptors. Conserved amino acid residues are shown in red.
Each transmembrane domain is boxed. Modified from Hondo et al. (2008).
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FIGURE 3 | Schematic representation of distribution of NPB/NPW
and Npbwr1 mRNA in mouse brain coronal sections. Receptor
distribution is shown in the right hemisphere, while ligand distribution is
shown in the left. Npb mRNA (red regions) was observed in the
hippocampus (CA1, CA2, CA3), lateral habenular nucleus (LHb),
paraventricular hypothalamic nucleus, medial parvicellular part (PaMP),
Edinger–Westphal (EW) nucleus, motor root of the trigeminal nerve (m5),
sensory root of the trigeminal nerve (s5), lateral parabrachial nucleus
alpha part (Sub CA), locus coeruleus (LC), noradrenergic cell group A5
(A5), and inferior olive subnucleus B (IOB) (Tanaka et al., 2003). Npw
mRNA (blue regions) was observed in the periaqueductal gray (PAG)
matter, EW nucleus (EW), ventral tegmental area (VTA), and dorsal raphe
nucleus (DR). NPBWR1 mRNA (yellow regions) was observed in the
claustrum (Cl), dorsal endopiriform nucleus (DEn), bed nucleus of the
stria terminals, laterodorsal part (BSTLD), bed nucleus of the stria
terminalis, medioventral part (BSTMV), suprachiasmatic nucleus (Sch),
magnocellular preoptic nucleus (MCPO), paraventricular hypothalamic
nucleus, posterior part (PaPo), dorsomedial hypothalamic nucleus (DM),
central amygdala (CeA), CA1 field, hippocampus (CA1), ventral tegmental
area (VTA), sensory root trigeminal nerve (Su5), subiculum (S), anterior
hypothalamic area, posterior part (AHP), and arcuate hypothalamic
nucleus (Arc). Modified from Hondo et al. (2008).
nucleus, dorsomedial hypothalamic nucleus, arcuate nucleus,
supraoptic retrochiasmatic nucleus, and in the area ventral to
the zona incerta (Schulz et al., 2007). Although Npb mRNA
was detected in several regions outside the hypothalamus such
as the hippocampus and brain stem (Tanaka et al., 2003; Jack-
son et al., 2006; Schulz et al., 2007), the existence of NPB-
immunoreactive neurons in these regions in the brain has not been
clearly demonstrated, since no good antibody for NPB is available.
In peripheral tissues, expression of human Npb mRNA was
detected by RT-PCR in the kidney, uterus, ovary, testis, and pla-
centa, while murine Npb mRNA was detected by Northern blot
at high levels in the stomach, spinal cord, and testis and at lower
levels in the liver and kidney (Brezillon et al., 2003). The biological
significance of this expression remains unknown.
NEUROPEPTIDE W
The existence of NPW in the mouse brain was more confined
to several nuclei in the midbrain and brainstem including the
EW, VTA, periaqueductal gray (PAG), and dorsal raphe nucleus
(DR) (Figure 3) (Tanaka et al., 2003; Kitamura et al., 2006). Most
of these neurons expressed tyrosine hydroxylase (TH), suggesting
that these cells are also catecholaminergic (our unpublished obser-
vation). In humans, high levels of Npw mRNA were detected in the
substantia nigra, and moderate expression levels were detected in
the amygdala and hippocampus (Fujii et al., 2002). In peripheral
tissues, expression of human Npw mRNA was confirmed by RT-
PCR in the progenital system, comprising the kidney, testis, uterus,
ovary, and placenta, and also in the stomach and respiratory sys-
tem, while murine Npw mRNA was detected by Northern blot at
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high levels in the lung and lower levels in the stomach (Brezillon
et al., 2003).
Consistent with the mRNA distribution,NPW-immunoreactive
(ir) cells were also exclusively detected in the EW, VTA, PAG, and
DR in rats (Kitamura et al., 2006). NPW-ir fibers were observed
in several brain regions in rats including the lateral septum, bed
nucleus of the stria terminalis (BNST), dorsomedial and posterior
hypothalamus, CeA, CA1 field of hippocampus, interpeduncu-
lar nucleus, inferior colliculus, lateral parabrachial nucleus, facial
nucleus, and hypoglossal nucleus. Among these regions, NPW-ir
fibers were most abundantly observed in the CeA and BNST, the
output nuclei of the extended amygdala. These observations sug-
gest that NPW-producing neurons are exclusively localized to the
mid brain, and they project mainly to the limbic system, especially
the CeA and BNST (Figure 3).
Some reports showed the existence of NPW-ir cell bodies in
the PVN in rats and mice (Dun et al., 2003). However, the staining
of NPW-like immunoreactivity-positive cells in the PVN is likely
to be non-specific staining, for two main reasons (Kitamura et al.,
2006). First, PVN immunoreactivity is also observed in NPW−/−
mice using many of the commercially available antibodies. Sec-
ond, Npw mRNA is not expressed in the PVN in either mice or
rats (Kitamura et al., 2006).
NPBWR1 (GPR7)
In situ hybridization study showed that the CeA and BNST express
the highest levels of NPBWR1 mRNA expression in the mouse
brain (Figure 3) (Tanaka et al., 2003; Singh et al., 2004; Jack-
son et al., 2006). Other nuclei with high levels of Npbwr1 are the
suprachiasmatic (SCN) and ventral tuberomammillary nuclei of
the hypothalamus. Moderate levels of expression are seen in the
CA1–CA3 regions of the hippocampus, dorsal endopiriform, dor-
sal tenia tecta, bed nucleus, and red nucleus. Low level expression
of Npbwr1 is seen in the olfactory bulb, parastrial nucleus, hypo-
thalamus, laterodorsal tegmentum, superior colliculus, LC, and
nucleus of the solitary tract.
NPBWR2 (GPR8)
Because Npbwr 2 does not exist in rodent genomes, very limited
information about the tissue distribution of NPBWR2 has been
available thus far. RT-PCR analysis showed that Npbwr2 mRNA
is strongly expressed in the human amygdala and hippocampus.
Lower levels of expression were also detected in the corpus callo-
sum, cerebellum, substantia nigra, and caudate nucleus (Brezillon
et al., 2003).
BIOLOGICAL ACTIVITIES OF NPB AND NPW
Several papers reported pharmacological actions of NPB and
NPW in vivo (Table 1). In this section, I discuss biological
activities of these peptides, referring the pharmacological actions
and phenotypes of genetically-modified mice on NPB/W systems
(Table 2).
FEEDING AND ENERGY HOMEOSTASIS
The NPB/W system was initially thought to be involved in regu-
lation of feeding behavior (Shimomura et al., 2002; Tanaka et al.,
2003), and therefore many of the currently available reports have
focused on the roles of NPB/W in this function. The first physio-
logical study on the action of NPW showed acute hyperphagia in
male rats when NPW was administered intracerebroventricularly
(i.c.v.) (Shimomura et al., 2002; Tanaka et al., 2003). However,
Tanaka et al. (2003) showed that the effect of NPB on feeding
behavior in mice is very complex. When NPB was i.c.v. injected
during the light period, no significant effect of NPB on feeding
was observed (Tanaka et al., 2003). In contrast, in the dark period,
i.c.v. administration of 3 nmol NPB increased feeding only within
the first 2 h. A higher dose of NPB suppressed food intake in
this period. After 2 h, both doses of NPB decreased food intake.
Because rodents only have NPBWR1 as a receptor for NPB, the
biphasic, i.e., earlier orexigenic and later anorexic, effect cannot
stem from the different potency rank orders of the two peptides on
NPBWR1 and NPBWR2. In fact, we also observed a similar bipha-
sic action of NPW on feeding behavior when administered i.c.v. in
mice or rats (our unpublished observation). Mondal et al. (2003)
also reported anorexic effects of NPW. These findings suggest a
complex role of NPB and NPW in the regulation of food intake.
Interestingly, the anorexic effect of NPB was markedly
enhanced when corticotrophin-releasing factor (CRF), a known
anorexic peptide, was co-administered (Tanaka et al., 2003). The
i.c.v. administration of these two peptides almost completely sup-
pressed food intake over 4 h. The biphasic effects of NPB/W on
feeding behavior and the synergistic anorexic effects of NPB and
CRF suggest complex roles of these peptides in the regulation of
feeding behavior in relation to the stress response. The synergic
effect of NPB with CRF in suppression of feeding suggests that
this neuropeptide is likely to be implicated in inhibition of feeding
under stressful conditions.
Continuous i.c.v. infusion of NPW was reported to suppress
feeding and body weight gain over the infusion period (Mondal
et al., 2003). Conversely, i.c.v. administration of anti-NPW IgG
stimulated feeding, suggesting that endogenous NPW plays an
inhibitory role in feeding behavior (Mondal et al., 2003). How-
ever, unlike the results of continuous i.c.v. infusion of NPW, bolus
intra-PVN microinjection of NPW23 at doses ranging from 0.1
to 3 nmol increased feeding for up to 4 h, and a bolus dose rang-
ing from 0.3 to 3 nmol was reported to increase feeding for up
to 24 h (Levine et al., 2005). These observations suggest that the
orexigenic versus anorectic effects of NPB/W could result from
different sites of action. When these peptides are injected into the
lateral ventricle, they might initially act on the PVN, followed by
diffusion to other regions implicated in the suppression of feeding.
Alternatively, delayed inhibition of feeding by NPB/W might result
from the production of other anorectic factors that are stimulated
by NPB or NPW.
The i.c.v. administration of NPW also increased body temper-
ature and heat production (Mondal et al., 2003). These effects
suggest that endogenous NPB/W might increase energy expendi-
ture, which is consistent with the late-onset obesity seen in male
NPBWR1−/−mice and NPB−/−mice (Ishii et al., 2003; Kelly et al.,
2005).
Male NPBWR1−/− mice have been shown to develop adult-
onset obesity that progressively worsens with age and is greatly
exacerbated when animals are fed a high-fat diet (Ishii et al.,
2003). The obesity is caused by hyperphagia along with decreased
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Table 1 | In vivo pharmacological effects of NPB/NPW.
Substance Effects Animal Preference
NPW (i.c.v.) Food intake ↑ Rat (male) Shimomura et al. (2002)
Body weight ↑ Tanaka et al. (2003)
NPW (i.c.v.) Body temperature ↑ Rat Mondal et al. (2003)
Heat production ↑
NPW ACTH ↑ Rat Hochol et al. (2007)
Estradiol ↑
NPW30 (i.c.v.) Arterial blood pressure (ABP) ↑ Rat Yu et al. (2007)
Heart rate (HR) ↑
Plasma catecholamine concentration ↑
NPB (i.c.v.) Food intake (light period–dark period) ↑ Mouse Tanaka et al. (2003)
NPB (i.c.v.) Prolactin ↑ Rat (male) Samson et al. (2004)
Growth hormone ↑
NPW23/NPB (i.t) Inflammatory pain ↓ Rat Yamamoto et al. (2005)
NPW/NPB (i.c.v.) Corticosterone in circulation ↑ Rat (male) Samson et al. (2004)
Taylor et al. (2005)
NPW/NPB (i.p) (Plasma level) parathyroid hormone ↑ Rat Hochol et al. (2007)
(Plasma level) corticosterone ↑
(Plasma level) testosterone ↑
NPW/NPB (i.c.v.) Circadian rhythm→ Rat/mouse Our unpublished observations
Table 2 | Summary of behavioral phenotypes of NPBWR1 knockout mice (modified from Nagata-Kuroiwa et al., 2011).
Behavioral test Parameter Results
Open field test Anxiety Normal time spent in center of arena
Elevated plus maze test Anxiety Normal time spent and number of entries in open arms
Light-dark exploration test Anxiety Decrease in escape latency and time spent in light box
Porsolt forced swim test Depression, learning helplessness Normal time spent swimming
Prepulse inhibition test Sensory motor reactivity Normal percentage of prepulse inhibition
Marble burying behavior test Compulsive behavior Normal number of marbles buried
Cued and contextual fear conditioning test Fear and memory Decrease in time of freezing behavior during contextual
testing while normal during auditory-cued testing
Morris water maze test Spatial memory Normal escape latency
Resident-intruder test Social interaction Abnormal social interaction (see text)
Stress-induced hyperthermia Stress response Exaggerated hyperthermia
Daily locomotor activity Circadian rhythm Normal in both light/dark cycle and constant dark condition.
Normal entrainment by food or light
Sleep-wake behavior (EEG/EMG) Sleep/wake cycle Normal in each episode duration, times spent in each state
in hourly sleep/wake analysis
energy expenditure. Npbwr1−/− male mice showed decreased
hypothalamic neuropeptide Y mRNA level and increased proo-
piomelanocortin mRNA level, a set of effects opposite to those
evident in ob/ob mice. Furthermore, ob/ob;NPBWR1−/− and
Ay/a;NPBWR1−/− double mutant male mice had an increased
body weight compared with normal ob/ob orAy/a male mice, sug-
gesting that the obesity of NPBWR1−/− mice is independent of
leptin and melanocortin signaling. Female mice did not show any
significant weight increase or associated metabolic defects. These
data suggest a potential role for NPBWR1 in regulating energy
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homeostasis independent of leptin and melanocortin signaling,
in a sexually dimorphic manner (Ishii et al., 2003). Consistent
with the phenotype of Npbwr1−/− mice, Npb−/− mice were also
reported to exhibit mild adult-onset obesity (Kelly et al., 2005).
PAIN REGULATION
Intracerebroventricular administration of NPB produces analge-
sia to pain induced by subcutaneous formalin injection in rats
(Tanaka et al., 2003). Intrathecal (i.t.) injection of either NPW23
or NPB also decreased agitation behaviors induced by formalin
injection into the paw and attenuated the level of mechanical allo-
dynia (Yamamoto et al., 2005). The effects were not antagonized
by naloxone, suggesting that this effect is not mediated through
the opioid receptor system. While i.t. injection of either NPW23
or NPB did not show any effect in the hot plate test or mechanical
nociceptive test, i.t. injection of either NPW23 or NPB signifi-
cantly suppressed the expression of Fos-like immunoreactivity of
the L4–5 spinal dorsal horn induced by formalin injection into
the paw. These data suggest that spinally applied NPW/B sup-
pressed the input of nociceptive information to the spinal dorsal
horn, producing an analgesic effect on inflammatory pain, but not
mechanical or thermal pain (Yamamoto et al., 2005).
Consistent with the pharmacological studies suggesting an
analgesic action of NPB on inflammatory pain, NPB−/− mice
exhibited hyperalgesia to inflammatory pain, while they showed
normal responses to mechanical or thermal pain (Kelly et al.,
2005). These observations suggest that NPB in the brain and/or
spinal cord modulates pain in a modality-specific manner. These
observations suggest that NPB might play a role in the pathophys-
iology of allodynia. Unfortunately, however there are no available
data about expression of NPW, NPW, or NPBWR1 in the spinal
cord or dorsal root ganglia.
A low level of NPBWR1 receptor expression was observed in
Schwann cells in both normal human and rat nerves as well as in
primary rat Schwann cell cultures. Peripheral nerve samples taken
from patients exhibiting inflammatory/immune-mediated neu-
ropathy showed a marked increase of NPBWR1 receptor expres-
sion restricted to myelin-forming Schwann cells. Complementary
animal models of immune-inflammatory and ligation-induced
nerve injury and neuropathic pain similarly exhibited increased
myelin-associated expression of NPBWR1 (Zaratin et al., 2005).
These observations suggest that NPBWR1 is involved in regulation
of inflammatory pain at least in part by modulating Schwann cell
function.
NEUROENDOCRINE REGULATION
Central administration of NPB or NPW elevated the plasma cor-
ticosterone level in rats (Samson et al., 2004; Taylor et al., 2005).
NPB also increased prolactin and decreased growth hormone
levels (Samson et al., 2004). Pretreatment with a polyclonal anti-
CRF antiserum or CRF antagonist completely blocked the effect
of NPB or NPW to stimulate ACTH release, and significantly
inhibited the effect of NPB/W on plasma corticosterone level
(Samson et al., 2004; Taylor et al., 2005). These findings suggest
that NPW and NPB play a role in the neuroendocrine response to
stress via activation of the hypothalamus-pituitary-adrenal (HPA)
axis. Consistent with these observations, whole cell patch-clamp
recording from hypothalamic slice preparations showed that bath
application of NPW depolarized and directly increased the spike
frequency of neuroendocrine PVN neurons (Taylor et al., 2005).
A whole cell patch-clamp study showed that NPW23 exhibited
effects on oxytocin, vasopressin, and thyrotrophin-releasing hor-
mone neurons in the PVN, although both depolarizing and hyper-
polarizing effects were observed in each of these cell groups (Price
et al., 2009). Corticotrophin-releasing hormone cells were unaf-
fected. Further subdivision of chemically phenotyped cell groups
into magnocellular, neuroendocrine, or pre-autonomic neurons,
using their electrophysiological fingerprints, revealed that neurons
projecting to medullary and spinal targets were predominantly
inhibited by NPW, whereas those that projected to the median
eminence or neural lobe showed almost equivalent numbers of
depolarizing and hyperpolarizing cells (Price et al., 2009).
The intracellular mechanisms of these electrophysiological
effects of NPW have remained unclear. Since NPBWR1 primarily
couples to Gi subclass of G-proteins, activation of this receptor
should lead to inhibition of neurons. Depolarizing effect of NPW
described in above mentioned report might be indirect effect due
to inhibition of inhibitory interneurons of recorded cells.
AUTONOMIC REGULATION
Intracerebroventricular administration of NPW to rats was
reported to increase arterial blood pressure (ABP), heart rate (HR),
and plasma catecholamine concentration (Yu et al., 2007). The
same report showed that most of the PVN neurons were excited,
while a subset of a smaller population of PVN neurons was inhib-
ited by NPW30, although the chemical identities of these neurons
were not determined. These observations suggest that NPB/W
modulate PVN neuronal activities, which play an important role
in regulation of the autonomic nervous system as well as the HPA
axis. The expression of NPB mRNA in the PVN suggests that NPB
is more likely to be involved in HPA axis regulation. However,
NPBWR1−/− mice have normal blood pressure and HR in a basal
state (Nagata-Kuroiwa et al., 2011). The physiological relevance of
the NPB/W system in regulation of the autonomic nervous system
remains unclear.
SLEEP ANDWAKEFULNESS
Neuropeptide B is reported to induce slow wave sleep in mice when
injected intracerebroventricularly (Hirashima et al., 2011). How-
ever, sinceNPBWR1−/−mice did not show any sleep abnormality,
the biological relevance of this finding remains unclear.
EMOTION AND BEHAVIOR
Npbwr1mRNA is abundantly expressed in discrete brain regions in
rodents, including the hypothalamus (dorsomedial hypothalamus
and suprachiasmatic nucleus), hippocampus, VTA, and extended
amygdala (the CeA and bed nucleus of the stria terminalis; BNST)
(Lee et al., 1999; Tanaka et al., 2003). These regions are implicated
in mood and emotion. Especially, the particularly strong expres-
sion of Npbwr1 in the CeA and BNST, together with the robust
projections of NPW-containing axons to these regions (Kitamura
et al., 2006), suggest that this receptor might be an important
modulator or regulator of the output signal from the extended
amygdala, which is a well-defined subcortical nuclear group that
is the center of emotion including fear (Phelps and LeDoux, 2005).
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A sensory stimulus associated with an aversive outcome will
change neural transmission in the amygdala to produce somatic,
autonomic, and endocrine signs of fear, as well as increased atten-
tion to that stimulus. Fear learning involves the lateral and baso-
lateral amygdala (BLA), where the association between incoming
sensory stimuli leads to potentiation of synaptic transmission.
The BLA receives sensory information from the thalamus, hip-
pocampus, and cortex, and then activates or modulates synaptic
transmission in target areas appropriate for the reinforcement sig-
nal with which the sensory information has been associated. The
BLA projects to the CeA and BSNT, whose efferents to the hypo-
thalamus and brainstem trigger the expression of fear. Histological
and electrophysiological studies have shown that NPBWR1 acts as
an inhibitory regulator on a subpopulation of GABAergic neurons
in the lateral division of the CeA and terminates stress responses
(Nagata-Kuroiwa et al., 2011). These anatomical and functional
findings suggest that the NPB/W systems might have important
roles in the modulation of output from the extended amygdala.
The role of NPBWR1 in social behavior was recently inves-
tigated using Npbwr1−/− mice (Nagata-Kuroiwa et al., 2011).
When presented with an intruder mouse,Npbwr1−/−mice showed
impulsive contact with the strange mice, produced more intense
approaches toward them, and had longer contact and chasing time
along with greater and sustained elevation of HR and blood pres-
sure compared to wild type mice. Npbwr1−/− mice also showed
increased autonomic and neuroendocrine responses to various
physical stresses, suggesting that NPBWR1 might play a role in
coping with stress.
Another interesting phenotype of NPBWR1−/− mice is the
impairment of contextual fear conditioning and inversion of
“safety conditioning.” In the safety conditioning paradigm, mice
received unpaired presentations of a CS (tone) and a US (electri-
cal shock). Because the shock never occurs during the CS, mice
typically learn to treat the CS as a safety signal, so that fear-related
behavior is inhibited during presentation of the CS. Npbwr1−/−
mice show an inversion of this learning in that the safety-trained
CS elicits fear rather than a reduction in fear. This observation
suggests that Npbwr1−/− mice undergo trace conditioning rather
than safety conditioning in this procedure, in that they associate
the CS and US across a long trace interval, while the control mice
treat CS and US as unpaired. These results suggest thatNpbwr1−/−
mice are more stimulus-bound, meaning that they preferentially
attend to discrete stimuli, to the exclusion of more complex,
conjunctive stimuli such as context. This hypothesis would also
explain the deficit in contextual fear conditioning. To determine
the neural mechanisms and the possible developmental and/or
extra-amygdalar origins of the phenotype, further investigation
using spatially restricted knockout mice and/or genetic rescue
of the phenotype of these mice by expressing NPBWR1 in a
region-specific manner is needed.
The human NPBWR1 gene has a frequent single nucleotide
polymorphism at nucleotide 404 (SNP rs33977775) in the cod-
ing region (404A>T). Importantly, this polymorphism causes an
amino acid substitution (Y135F) within the highly conserved DRY
motif of G-protein-coupled receptors at the junction of the third
transmembrane domain and second intracellular loop, which is
known to play an important role in G-protein coupling. Recently,
Watanabe et al. (2012) demonstrated that this change partially
impairs receptor function as measured by inhibition of cAMP
production. Furthermore, this variation affects the emotional
response to stimuli showing human faces with four categories of
emotional expression (anger, fear, happiness, and neutral). The
subject’s emotional levels at seeing these faces were rated on scales
of hedonic valence, emotional arousal, and dominance (V–A–D).
A significant genotype difference was observed in valence eval-
uation; the 404AT group (position 404 in one allele is replaced
by T) perceived the face as more pleasant than did the 404AA
group (position 404 in both alleles of NPBWR1 is A), regardless of
the category of facial expression. The 404AT group tended to feel
less submissive to an angry face than did the 404AA group. These
results suggest that a single nucleotide polymorphism of NPBWR1
seems to affect human behavior in a social context. Future studies
using functional brain imaging of human subjects are needed to
clarify the mechanisms of the effects of the polymorphisms.
EFFECTS ON CIRCADIAN RHYTHM
The abundant expression of NPBWR1 in the suprachiasmatic
nucleus suggests the possibility that this neuropeptides/receptor
system has a role in regulating circadian rhythm (Lee et al., 1999;
Tanaka et al., 2003; Singh et al., 2004). However, we did not observe
any effects of NPB/W on circadian activity in rats or mice when
administered by i.c.v. injection. Npbwr1−/− mice displayed a nor-
mal circadian pattern of behavior in both light-dark and constant
dark conditions (Uchio et al., 2009). Both light-entrainable and
food-entrainable oscillation were also normal in these mice (our
unpublished observations). The function of NPBWR1 in the SCN
remains unclear thus far.
PERIPHERAL ACTIONS
Expression of Npb, Npw, and Npbwr1 mRNA in both the adrenal
cortex and adrenal medulla has been reported (Andreis et al.,
2005; Mazzocchi et al., 2005; Hochol et al., 2007). NPB and NPW
were shown to pharmacologically stimulate adrenal glucocorti-
coid secretion by an ACTH-independent mechanism. It was also
reported that NPW stimulates in vitro aldosterone secretion by
enhancing the release of medullary catecholamines, which activate
beta-adrenoceptors located on zona glomerulosa cells (Hochol
et al., 2007).
Bolus intraperitoneal (i.p.) injection of NPB or NPW increased
the plasma levels of parathyroid hormone, corticosterone, and
testosterone. NPB was also reported to increase the blood concen-
tration of thyroxine, and NPW was shown to increase ACTH and
estradiol levels. These findings suggest that NPB and NPW play a
role in regulation of the endocrine system (Hochol et al., 2006).
The existence of NPW in rat gastric antral cells was reported.
The level of NPW in the stomach was decreased in fasted animals,
while it was increased by re-feeding (Mondal et al., 2003), which
is consistent with the notion that NPW may act as a suppressant
of feeding. However, we did not observe any effects on feeding
in mice when NPB or NPW was intravenously administered, sug-
gesting that peripheral NPB/W has limited, if any, significant role
in modulating feeding behavior (our unpublished observations).
Neuropeptide B and NPW are reported to inhibit proliferative
activity of rat calvarial osteoblast-like (ROB) cells (Ziolkowska
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et al., 2009). However, the physiological relevance of this finding
is unknown, and requires further investigation.
CONCLUSION
Neuropeptide B and NPW are likely to be multi-tasking fac-
tors. Both Npb−/− and Npbwr1−/− mice show late-onset obesity
and hyperphagia, suggesting that the endogenous NPB-NPBWR1
pathway negatively regulates feeding behavior and positively reg-
ulates energy expenditure (Ishii et al., 2003; Kelly et al., 2005).
This notion is further supported by several pharmacological stud-
ies that showed that i.c.v. NPB/W increased heat production and
sympathetic outflow (Yu et al., 2007). However, the biphasic (early
orexigenic followed by anorexic) effects of NPB/NPW suggest
complex actions of NPB and NPW in the regulation of food intake.
Many studies have also shown that the NPB/W system is
involved in the modulation of inflammatory pain. Consistent with
these results, Npb−/− mice are hypersensitive to inflammatory
pain but display no significant difference in chemical or thermal
pain. These data together strongly support a physiological role
of central NPB in pain regulation, and agonists for NPBWR1 or
NPBWR2 might be good candidates for analgesic drugs for chronic
inflammatory pain.
Finally, the strong, discrete expression of NPBWR1 in the
extended amygdala and abundant projections of NPW fibers in
these regions suggest that this neuropeptide system has a role in the
regulation of fear and anxiety. The CeA and BNST have been impli-
cated in a variety of emotional functions including expression of
fear, modulation of memory, and mediation of social communi-
cation (Davis and Shi, 1999) (Figure 3). Therefore, the expression
of NPBWR1 in the CeA and BNST suggests modulatory roles of
this receptor in these functions. Recent studies inNpbwr1−/−mice
support this concept (Table 2). Furthermore, a recent report sug-
gested that a human polymorphism in the NPBWR1 gene might
affect emotional responses to facial expressions (Watanabe et al.,
2012). In daily life, people show various emotional reactions to
others depending on their personalities, even in the same situa-
tion. NPBWR1 may provide part of the cause for such differences
in reactions in social interactions.
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